Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors

IntroductionNeuroendocrine neoplasms including neuroendocrine tumors (NETs) are often diagnosed as primary disseminated or inoperable. In those cases, systemic extensive therapy is necessary, but radical treatment is unlikely. As described in the literature, in some selected cases, peptide receptor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marta Opalińska, Anna Sowa-Staszczak, Anna Grochowska, Helena Olearska, Alicja Hubalewska-Dydejczyk
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	inoperable neuroendocrine tumors PRRT neoadjuvant therapy NEN NET (neuroendocrine tumors) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1254a0f6a8cc42f8becf30fad0bed1c7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1254a0f6a8cc42f8becf30fad0bed1c7
record_format	dspace
spelling	oai:doaj.org-article:1254a0f6a8cc42f8becf30fad0bed1c72021-11-12T06:20:32ZValue of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors2234-943X10.3389/fonc.2021.687925https://doaj.org/article/1254a0f6a8cc42f8becf30fad0bed1c72021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.687925/fullhttps://doaj.org/toc/2234-943XIntroductionNeuroendocrine neoplasms including neuroendocrine tumors (NETs) are often diagnosed as primary disseminated or inoperable. In those cases, systemic extensive therapy is necessary, but radical treatment is unlikely. As described in the literature, in some selected cases, peptide receptor radionuclide therapy (PRRT) may be used as a first-line/neoadjuvant therapy that allows further successful surgery. Such treatment may enable a reduction of total tumor burden or allow a radical treatment which improves the final outcomes.AimThis study aims to assess whether neoadjuvant PRRT could be a treatment option for patients with initially unresectable NETs.MethodsAmong the group of 114 patients treated with PRRT between the years 2005 and 2020, in 32 cases, it was the first-line therapy, mainly due to massive disease burden at the time of diagnosis. Among them, nine patients received PRRT as the first-line treatment due to the primary inoperable tumors with the intention of preoperative reduction of the tumor size in order to allow for a surgical treatment.ResultsNeoadjuvant PRRT enabled surgery in four out of nine (45%) patients. Finally, in two out of four cases, the goal (radical surgery) has been achieved.ConclusionPRRT may be considered not only as a palliative but also as a neoadjuvant therapy in advanced, somatostatin-positive NETs that were initially inoperable.Marta OpalińskaAnna Sowa-StaszczakAnna GrochowskaHelena OlearskaAlicja Hubalewska-DydejczykFrontiers Media S.A.articleinoperable neuroendocrine tumorsPRRTneoadjuvant therapyNENNET (neuroendocrine tumors)Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	inoperable neuroendocrine tumors PRRT neoadjuvant therapy NEN NET (neuroendocrine tumors) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	inoperable neuroendocrine tumors PRRT neoadjuvant therapy NEN NET (neuroendocrine tumors) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Marta Opalińska Anna Sowa-Staszczak Anna Grochowska Helena Olearska Alicja Hubalewska-Dydejczyk Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
description	IntroductionNeuroendocrine neoplasms including neuroendocrine tumors (NETs) are often diagnosed as primary disseminated or inoperable. In those cases, systemic extensive therapy is necessary, but radical treatment is unlikely. As described in the literature, in some selected cases, peptide receptor radionuclide therapy (PRRT) may be used as a first-line/neoadjuvant therapy that allows further successful surgery. Such treatment may enable a reduction of total tumor burden or allow a radical treatment which improves the final outcomes.AimThis study aims to assess whether neoadjuvant PRRT could be a treatment option for patients with initially unresectable NETs.MethodsAmong the group of 114 patients treated with PRRT between the years 2005 and 2020, in 32 cases, it was the first-line therapy, mainly due to massive disease burden at the time of diagnosis. Among them, nine patients received PRRT as the first-line treatment due to the primary inoperable tumors with the intention of preoperative reduction of the tumor size in order to allow for a surgical treatment.ResultsNeoadjuvant PRRT enabled surgery in four out of nine (45%) patients. Finally, in two out of four cases, the goal (radical surgery) has been achieved.ConclusionPRRT may be considered not only as a palliative but also as a neoadjuvant therapy in advanced, somatostatin-positive NETs that were initially inoperable.
format	article
author	Marta Opalińska Anna Sowa-Staszczak Anna Grochowska Helena Olearska Alicja Hubalewska-Dydejczyk
author_facet	Marta Opalińska Anna Sowa-Staszczak Anna Grochowska Helena Olearska Alicja Hubalewska-Dydejczyk
author_sort	Marta Opalińska
title	Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
title_short	Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
title_full	Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
title_fullStr	Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
title_full_unstemmed	Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
title_sort	value of peptide receptor radionuclide therapy as neoadjuvant treatment in the management of primary inoperable neuroendocrine tumors
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/1254a0f6a8cc42f8becf30fad0bed1c7
work_keys_str_mv	AT martaopalinska valueofpeptidereceptorradionuclidetherapyasneoadjuvanttreatmentinthemanagementofprimaryinoperableneuroendocrinetumors AT annasowastaszczak valueofpeptidereceptorradionuclidetherapyasneoadjuvanttreatmentinthemanagementofprimaryinoperableneuroendocrinetumors AT annagrochowska valueofpeptidereceptorradionuclidetherapyasneoadjuvanttreatmentinthemanagementofprimaryinoperableneuroendocrinetumors AT helenaolearska valueofpeptidereceptorradionuclidetherapyasneoadjuvanttreatmentinthemanagementofprimaryinoperableneuroendocrinetumors AT alicjahubalewskadydejczyk valueofpeptidereceptorradionuclidetherapyasneoadjuvanttreatmentinthemanagementofprimaryinoperableneuroendocrinetumors
_version_	1718431152534978560

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors

Ejemplares similares